
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
+6
Arch Therapeutics, Inc. (OTCQB:ARTH) is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch has received regulatory authorization to market AC5 Advanced Wound System and AC5 Topical Hemostat as medical devices in the United States and Europe, respectively. Archs development stage product candidates include AC5-GTM, AC5-V and AC5 Surgical Hemostat, among others.1,2 1 AC5-G, AC5-V, and AC5 Surgical Hemostat are currently investigational...
Biotechnology,wound care,interventional healthcare,hemostasis,sealants,self-assembling peptide technology,ac5,dermal science,biosurgery,surgery,and trauma
Arch therapeutics, inc (otcqb:arth) operates in the Biotechnology research industry.
Arch therapeutics, inc (otcqb:arth)'s revenue is < 1m
Arch therapeutics, inc (otcqb:arth) has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.